Semaglutide Dosage Chart & Titration Schedules

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosage follows a standard titration schedule starting at 0.25 mg weekly, increasing by 0.25 mg every four weeks until reaching a therapeutic dose of 0.5–2.4 mg. However, individual response to dosing varies significantly based on metabolic factors, body composition, and genetic predispositions in peptide signaling pathways.

Understanding your own metabolic and genetic context helps you work with your provider to evaluate whether standard titration, dose adjustments, or alternative formulations align with your health goals. PlexusDx combines dosing education with personalized genetic insights to support more informed treatment conversations.

Standard Semaglutide Titration Schedule and Dosing Ranges

The FDA-approved titration protocol for semaglutide begins at 0.25 mg once weekly for four weeks, followed by 0.25 mg increments every four weeks. Most patients reach maintenance doses of 0.5–2.4 mg weekly, though some remain effective at lower doses while others require higher therapeutic ranges.

Compounded semaglutide follows similar titration principles but may be customized based on individual tolerance, provider guidance, and response markers. The goal is finding the lowest effective dose that balances efficacy with side effect tolerability over a 12–16 week titration period.

Factors Influencing Individual Dosage Requirements

Semaglutide response depends on multiple biological factors beyond body weight, including baseline metabolic rate, insulin sensitivity, gut motility, appetite regulation genes, and prior medication exposure. Individuals with different genetic variants in GLP-1R signaling may experience different thresholds for satiety, gastric emptying, and glycemic response.

Baseline biomarkers—including fasting glucose, HbA1c, insulin levels, and inflammatory markers—provide context for understanding where you fall on the response spectrum. These factors inform provider conversations about optimal starting doses and expected titration timelines.

Dosage Factor	Clinical Impact on Titration
GLP-1R Genetic Variants	May influence receptor sensitivity and response threshold to standard doses
Baseline Insulin Resistance	Higher baseline IR may require higher effective doses or slower titration
Prior GLP-1 Exposure	Previous GLP-1 use may reduce initial response or require adjusted escalation
Gastrointestinal Tolerance	Nausea/vomiting history may necessitate slower titration or microdose protocols
Body Composition & Metabolism	Lean mass, metabolic rate, and fat distribution affect dosage efficacy

Compounded vs. Standard Dosing: Flexibility and Personalization

Compounded semaglutide from licensed 503A pharmacies allows more granular dose customization than pre-filled pens, supporting individualized titration when standard increments don't align with your response. Some patients benefit from microdose protocols (0.1–0.2 mg) or off-label dose adjustments based on biomarker response.

Compounded formulations cost between $149 monthly and can be adjusted mid-titration without waiting for new prescriptions. This flexibility enables providers to fine-tune dosing based on real-world tolerability and efficacy feedback, particularly for patients who experience side effects at standard increment intervals.

Safety Considerations and Who Needs Provider Oversight

Semaglutide requires medical supervision before initiation and during titration. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and certain gastrointestinal disorders. Dose adjustments may be necessary in kidney or liver disease and concurrent diabetes medications.

Common titration-phase side effects—nausea, vomiting, constipation—often resolve within 2–4 weeks but warrant provider communication if severe. Dosage modifications, timing adjustments, or temporary pauses support adherence and safety, especially in early titration weeks. Your provider should reassess tolerance and efficacy at each dose increment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1R signaling (such as GLP1R rs6923761) and appetite regulation pathways (including MC4R rs17782313 and FTO rs9939609) that may provide context for individual dosage response. These predispositions may help inform conversations with your provider about whether standard titration, slower escalation, or alternative formulations align with your metabolic profile.

The genetic test does not predict exact semaglutide response or determine optimal dosage for you individually. Instead, it reveals predispositions in peptide signaling and metabolic pathways that, when interpreted with clinical biomarkers and your health history, can support a more personalized conversation with your provider about dosing strategy.

Combining genetic insights with baseline metabolic markers—fasting glucose, insulin, inflammatory markers—and ongoing titration feedback creates a comprehensive picture for provider decision-making. This precision-wellness approach helps ensure dosing adjustments align with your individual biology rather than relying on population averages alone.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical semaglutide starting dose and titration timeline?

Standard titration begins at 0.25 mg weekly for four weeks, increasing by 0.25 mg every four weeks until reaching a therapeutic dose of 0.5–2.4 mg. Full titration typically spans 12–16 weeks, though individual timelines vary based on tolerance and provider guidance.

Can semaglutide dosage be customized below 0.25 mg starting doses?

Yes. Compounded semaglutide allows microdose protocols starting at 0.1–0.2 mg weekly, useful for patients experiencing nausea at standard doses or those with high GLP-1R sensitivity. Your provider can adjust compounded doses more flexibly than pre-filled pens.

How does the PlexusDx Precision Peptide Genetic Test relate to semaglutide dosing?

The test reveals genetic predispositions in GLP-1R signaling and appetite regulation (GLP1R, MC4R, FTO variants) that may provide context for provider conversations about titration strategy. It does not predict your exact response but supports personalized dosing discussions. The genetic test costs $99 as an add-on or $298 standalone.

What side effects occur during semaglutide titration and how are they managed?

Nausea, vomiting, and constipation are common during early titration but often resolve within 2–4 weeks. If side effects persist, your provider may slow titration pace, adjust timing, or modify concurrent medications. Severe symptoms warrant immediate provider contact.

Why do some patients need higher semaglutide doses than others?

Individual dosage needs depend on GLP-1R receptor sensitivity, baseline insulin resistance, prior GLP-1 exposure, gastrointestinal function, and overall metabolic rate. Genetic variants in GLP1R and metabolic genes influence response thresholds. Baseline biomarkers and titration feedback guide individualized dose selection.

Semaglutide Dosage Chart: Biomarker Context and Personalized Titration